Thrombin generation in vivo and ex vivo in sickle cell disease patients.

Autor: Ladeira VS; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil; Fundação Hemominas, Minas Gerais, Brazil., de Oliveira Toledo SL; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Ferreira LGR; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Oliveira MM; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil; Fundação Hemominas, Minas Gerais, Brazil., Silva APF; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., de Oliveira WV Jr; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Duarte RCF; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil., Renó CO; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Dusse LMS; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil., Dos Santos HL; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Carvalho MDG; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Brazil., Pinheiro MB; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil., Rios DRA; Universidade Federal de São João del-Rei, Campus Centro Oeste Dona Lindu, Brazil. Electronic address: danyelleromana@ufsj.edu.br.
Jazyk: angličtina
Zdroj: Thrombosis research [Thromb Res] 2021 Jan; Vol. 197, pp. 165-171. Date of Electronic Publication: 2020 Nov 07.
DOI: 10.1016/j.thromres.2020.10.040
Abstrakt: Activation of coagulation is an important hallmark of sickle cell disease (SCD) and it is believed that hypercoagulability plays a role to the disease pathophysiology. Studies have sought to identify how hemostatic biomarkers are expressed in SCD, however, the results are inconclusive. In this context, our objective was to evaluate the thrombin generation in vivo and ex vivo in SCD patients and the association between these biomarkers and the use of HU. This cross-sectional study was carried out with patients diagnosed with SCD, users or not of Hydroxyurea (HU), and healthy individuals as controls. D dimer (D-Di) was evaluated by ELISA and (TGT) thrombin generation test by CAT method. D-Di plasma levels were significantly higher in SCD patients when compared to the controls. TGT parameters such as peak, ETP and normalized ETP at low TF concentration and time-to-peak, peak, ETP and normalized ETP values at high TF concentration were lower in SCD patients than in controls. In contrast, the normalized activated protein C sensitivity ratio (nAPCsr) was higher in patients compared to controls, indicating resistance to the action of this natural anticoagulant. Regarding the use of HU, comparing users and non-users of this drug, no difference was observed in D-Di levels and in most TGT parameters. Our data analyzed together allow us to conclude that patients with SCD present a state of hypercoagulability in vivo due to the higher levels of D-Di and resistance to APC assessed ex vivo which is consistent with the coagulation imbalance described in SCD patients.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: